

---

## Camurus - A Swedish Biotech Success Story

Redeye initiates coverage of Camurus, a biotech company that made it from start-up to large cap, currently profitable with a cumulative annual growth rate of 54% for 2020–2024 in the opioid use disorder market, a still strong outlook and a blockbuster pipeline.

**Read more and download the Research Report.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

**Camurus - A Swedish Biotech Success Story**